Pendapatan sadurunge ngurangi bunga, pajak, lan amortisasi: Exicure, Inc. (XCUR)
Exicure, Inc. (XCUR) focuses on developing nucleic acid-based therapeutics, relying on grants and external capital. The operating cash flow reflects current trends, where 0.00 determines this specific parameter level. The company implements bioethical standards and sustainable laboratory practices. However, following restructuring, the business has stagnated at a low efficiency level while striving to minimize internal costs.
Ringkesan rincian data analitis Exicure (XCUR)
- rega pasar lan target rega analis:
- indikator kapitalisasi bursa perusahaan:
- informasi kapitalisasi buku:
- rincian struktur utang lan likuiditas bisnis:
Koefisien Total Utang marang Modal Exicure, Inc.|XCUR - Utang jangka dawa marang ekuitas|Rasio utang jangka cendhak marang modal Exicure Inc.|XCUR - Gunggung utang perusahaan|Utang marang nilai buku Exicure|XCUR - Kewajiban jangka dawa perusahaan|Gunggunge utang jangka cendhak Exicure|Rasio likuiditas darurat exicuretx.com
- rincian bathi lan kelipatan pasar:
XCUR - Bathi resik|Bathi mangsa ngarep Exicure, Inc.|XCUR - Koefisien rega marang bathi|Pangali Forward P/E Exicure Inc.|XCUR - Rasio rega marang bathi tumrap wutah|Nilai bisnis marang bathi operasional sadurunge panyusutan Exicure|XCUR - Bathi operasional EBITDA|Bathi saben saham sajrone 12 wulan pungkasan Exicure|XCUR - Bathi saben saham sajrone rolas wulan pungkasan|Wutah bathi saben saham taun-ka-taun sajrone 12 wulan pungkasan exicuretx.com|XCUR - Wutah bathi ing taun lumaku|Prakiraan wutah bathi kanggo taun ngarep Exicure, Inc.
Ringkesan analitik perusahaan:XCUR - Exicure, Inc.
For the long-term investor, the reliability of Exicure, Inc. (XCUR) is determined by its ability to generate cash flow amidst volatile demand for nucleic acid delivery platforms. When analyzing the operating profit (EBIT) trend, one must consider the difference between revenue and direct costs, which allows for an assessment of the effectiveness of new licensing agreements and the overall resilience of the business to market shocks.
Analisis pesaing Exicure, Inc.
Bathi operasional EBITDA Tempus TEM|QGEN - Bathi sadurunge mbayar bunga, pajak, lan amortisasi|Pendapatan sadurunge ngurangi bunga, pajak, lan amortisasi IONS (ionispharma.com)|RGEN: Bathi operasional EBITDA|Bathi sadurunge bunga, pajak, lan amortisasi Avidity Biosciences Inc (RNA)|Bathi operasional sadurunge ngurangi amortisasi CRSP|WGS: Pendapatan sadurunge ngurangi bunga, pajak, lan amortisasi|Bathi operasional EBITDA RARE|Pendapatan operasional sadurunge ngurangi amortisasi beamtx.com|Bathi sadurunge mbayar bunga, pajak, lan amortisasi Sarepta SRPT|TWST: Bathi operasional sadurunge amortisasi|10x Genomics Corp - Bathi operasional EBITDA|Intellia Corp (NTLA) - Bathi operasional sadurunge ngurangi amortisasi|STOK (Stoke Therapeutics) - Bathi operasional sadurunge ngurangi amortisasi|BLFS - Pendapatan operasional sadurunge ngurangi amortisasi|Bathi operasional sadurunge ngurangi amortisasi WVE|Bathi operasional sadurunge amortisasi MAZE (Maze Therapeutics, Inc.)|Bathi operasional EBITDA SION|Bathi operasional sadurunge ngurangi amortisasi Prime Medicine Bio PRME|Taysha Gene Therapies - Bathi operasional sadurunge ngurangi amortisasi|Bathi operasional EBITDA uniqure.com QURE|MGTX - Bathi sadurunge mbayar bunga, pajak, lan amortisasi|Pendapatan sadurunge ngurangi bunga, pajak, lan amortisasi RGNX (REGENXBIO Inc)|SLDB: Bathi operasional EBITDA|Bathi operasional sadurunge amortisasi OCGN|Bathi sadurunge mbayar bunga, pajak, lan amortisasi Pacific Biosciences|Bathi operasional sadurunge amortisasi BNTC (benitec.com)|Bathi operasional EBITDA DSGN|Bathi operasional EBITDA Rocket Pharma (RCKT)|Bathi operasional EBITDA FDMT (4D Molecular Therapeutics Inc)|Lexeo Therapeutics Inc. (LXEO) - Bathi sadurunge bunga, pajak, lan amortisasi|KRRO: Bathi operasional sadurunge ngurangi amortisasi|EDIT (editasmedicine.com) - Bathi operasional sadurunge amortisasi|SLN: Bathi operasional EBITDA|PRQR - Pendapatan operasional sadurunge ngurangi amortisasi|CDXS (Codexis Inc) - Bathi operasional EBITDA|Bathi operasional sadurunge ngurangi amortisasi Sangamo BioSciences (SGMO)|Bathi operasional sadurunge ngurangi amortisasi NAUT (Nautilus Biotechnology)|Bathi operasional EBITDA metagenomi.co (MGX)|Bathi sadurunge mbayar bunga, pajak, lan amortisasi Precision BioSciences, Inc. DTIL|Pendapatan sadurunge ngurangi bunga, pajak, lan amortisasi GBIO|Boundless Bio, Inc - Bathi operasional EBITDA|Bathi sadurunge bunga, pajak, lan amortisasi Imunon, Inc.|PHIO (phiopharma.com) - Bathi operasional sadurunge ngurangi amortisasi|Mustang Bio - Pendapatan sadurunge ngurangi bunga, pajak, lan amortisasi|RNAZ (TransCode Therapeutics Inc.) - Bathi operasional EBITDA|Bionano (BNGO) - Pendapatan operasional sadurunge ngurangi amortisasi|Bathi sadurunge mbayar bunga, pajak, lan amortisasi Applied DNA (APDN)|bluebird bio, Inc - Bathi operasional sadurunge amortisasi|Bathi operasional EBITDA IPA (ImmunoPrecise Antibodies Ltd.)|OMGA - Bathi operasional sadurunge ngurangi amortisasi|OMIC: Bathi operasional sadurunge ngurangi amortisasi|Pendapatan operasional sadurunge ngurangi amortisasi Regulus Therapeutics, Inc. RGLS|SYRS (Syros) - Bathi operasional sadurunge ngurangi amortisasi|Bathi operasional sadurunge amortisasi TBIO|TCON (TRACON Pharmaceuticals) - Bathi operasional EBITDA|Bathi operasional sadurunge ngurangi amortisasi unitybiotechnology.com (UBX)
